Currently, inhibition of the proteasome has been validated as a promising approach in anticancer therapy.
Simulation results have been validated as a result of experimental investigations.
The polyamine biosynthetic pathway of protozoan parasites has been validated as a target in antiparasitic chemotherapy.
DNA topoisomerase I (Topo I) has been validated as a target for anticancer agents.
STAT3 signaling pathway has been validated as a vital therapeutic target for cancer therapy.
Inhibition of phosphodiesterase 5A (PDE5A) has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD).
In particular, the passive clustering (PC) mechanism has been validated as a more efficient approach compared to traditional clustering mechanisms.
The interaction between HIV-1 integrase and LEDGF/P75 has been validated as a target for anti-HIV drug development.
Late lumen loss, as determined by QCA, has been validated as a surrogate for clinical endpoints such as target vessel revascularization.
18F-F DGal PET/CT has been validated as a functional measure in pigs [10], healthy human subjects [11], and patients with cirrhosis [4].
As a well known metabolic radiotracer for oxygen consumption, [11C]acetate has also been validated as a radiotracer for MBF imaging in humans and rats.
